154
Views
0
CrossRef citations to date
0
Altmetric
Original Articles

Clinical Outcomes in Vitrectomized versus Non-vitrectomized Eyes in Patients with Primary Vitreoretinal Lymphoma

, MD, , MDORCID Icon, , , MS, , BS, , MD, , MD, PhD, , MD & , MD show all
Pages 496-500 | Received 31 Aug 2021, Accepted 18 Jan 2022, Published online: 24 Feb 2022

References

  • Grimm SA, Pulido JS, Jahnke K, et al. Primary intraocular lymphoma: an international primary central nervous system lymphoma collaborative group report. Ann Oncol. 2007;18:1851–1855. doi:10.1093/annonc/mdm340.
  • Pulido JS, Johnston PB, Nowakowski GS, et al. The diagnosis and treatment of primary vitreoretinal lymphoma: a review. Int J Retina Vitreous. 2018;7(4):18. doi:10.1186/s40942-018-0120-4.
  • Sagoo MS, Mehta H, Swampillai AJ, et al. Primary intraocular lymphoma. Surv Ophthalmol. 2014;59:503–516. doi:10.1016/j.survophthal.2013.12.001.
  • Tang L-J, Gu C-L, Zhang P. Intraocular lymphoma. Int J Ophthalmol. 2017;10:1301–1307. doi:10.18240/ijo.2017.08.19.
  • Coupland SE, Chan CC, Smith J. Pathophysiology of retinal lymphoma. Ocul Immunol Inflamm. 2009;17(4):227–237. doi:10.1080/09273940903168696.
  • Venkatesh P, Gogia V, Khanduja S, et al. Therapeutic vitrectomy for vitreal recurrence of intraocular lymphoma resistant to intravitreal methotrexate post systemic chemotherapy. J Can Res Ther. 2015;11:668. doi:10.4103/0973-1482.140824.
  • Iaccheri B, Fiore T, Cerquaglia A, et al. Transient therapeutic effect of vitrectomy in primary intraocular lymphoma. Int Ophthalmol. 2017;37:1333–1335. doi:10.1007/s10792-016-0405-2.
  • Bever GJ, Kim DJ, Afshar AR, et al. Therapeutic vitrectomy as an adjunct treatment to systemic chemotherapy for intraocular lymphoma. Retin Cases Brief Rep. 2020;14(2):116–119. doi:10.1097/ICB.0000000000000668.
  • Bach M, Schulze-Bonsel K, and Feltgen N, et al. Author response: numerical imputation for low vision states. Invest. Ophthalmol. Vis. Sci. 2007;eLetter:2.
  • Nussenblatt RB, Palestine AG, Chan CC, Roberge F. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology. 1985;92:467–471. doi:10.1016/S0161-6420(85)34001-0.
  • Riemens A, Bromberg J, Touitou V, et al. Treatment strategies in primary vitreoretinal lymphoma: a 17-Center European collaborative study. JAMA Ophthalmol. 2015;133:191–197. doi:10.1001/jamaophthalmol.2014.4755.
  • Farrall AL, Smith JR. Eye involvement in primary central nervous system lymphoma. Surv Ophthalmol. 2020;65(5):548–561. doi:10.1016/j.survophthal.2020.02.001.
  • Hormigo A, Abrey L, Heinemann M-H, DeAngelis LM. Ocular presentation of primary central nervous system lymphoma: diagnosis and treatment. Br J Haematol. 2004;126:202–208. doi:10.1111/j.1365-2141.2004.05028.x.
  • Khan K, Jayaswal R, Madhusudhan S, Gibran SK. Macular OCT changes after vitrectomy. Ophthalmology. 2007;114:1955–1955.e1. doi:10.1016/j.ophtha.2007.04.033.
  • Kvopka M, Lake SR, Smith JR. Intraocular chemotherapy for vitreoretinal lymphoma: a review. Clin Exp Ophthalmol. 2020;48(2):240–248. doi:10.1111/ceo.13668.
  • Chan -C-C, Wallace DJ. Intraocular lymphoma: update on diagnosis and management. Cancer Control. 2004;11:285–295. doi:10.1177/107327480401100502.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.